RecruitingPhase 1Phase 2NCT06085729
Phase I/II Study of PEGylated Arginine Deiminase (ADI-PEG20) With Carboplatin and Cabazitaxel in Men With Aggressive Variant Prostate Cancers (AVPC)
Sponsor
M.D. Anderson Cancer Center
Enrollment
30 participants
Start Date
Feb 29, 2024
Study Type
INTERVENTIONAL
Conditions
Summary
To find the best dose of ADI-PEG20 that can be given in combination with carboplatin and cabazitaxel to patients with AVPC.
Eligibility
Sex: MALEMin Age: 18 Years
Plain Language Summary
Simplified for easier understanding
This clinical trial is studying a drug called ADI-PEG 20, a drug called Cabazitaxel, and others for people with prostate cancer. The study is currently recruiting participants at 1 location. People eligible for this study include men aged 18 Years and older.
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGADI-PEG 20
Given by Injection
DRUGCabazitaxel
Given by IV (vein)
DRUGCarboplatin
Given by IV (vein)
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06085729
Related Trials
Comparing Two Different Boost Approaches in Radiation Therapy for People With Prostate Cancer
NCT075481648 locations
A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation
NCT06952803342 locations
Focal Therapy With Stereotactic Body Radiation Therapy (SBRT) for Patients With a Single Prostate Tumor
NCT056166501 location
Care of the Prostate Cancer Patient and Prospective Procurement of Prostate Cancer Tissue
NCT025942021 location
Prospective Monitoring of Subjects With Biochemically Recurrent Prostate Cancer Using 18FDCFPyL
NCT055881281 location